Abstract:Sarah Balboul, 1 Julia Kahn, 1 Alexis Tracy, 2 Anjelica Peacock, 3 Abigail Cline 2– 4 1 School of Medicine, New York Medical College, Valhalla, NY, USA; 2 Department of Dermatology, New York Medical College, Valhalla, NY, USA; 3 Department of Dermatology, Metropolitan Medical Center, New York, NY, USA; 4 Department of Dermatology, Lincoln Medical Center, Bronx, NY, USA Correspondence: Abigail Cline, Email Background: While dupilumab has shown efficacy in improving atopic dermatitis, few studies have assessed the long-term clinical data of dupilumab use in pediatric patients. Objective: In the present study, we reviewed the current literature to assess reported efficacies, side effects, and risks of using dupilumab to treat atopic dermatitis in pediatric populations. Methods: Using PRISMA guidelines, the authors searched PubMed/MEDLINE and Embase for studies related to dupilumab treatment for atopic dermatitis in pediatric patients aged 6– 11 years old. Results: A total of 512 pediatric patients (ages 6– 11) were included. Outcome measures assessed by EASI, SCORAD, P-NRS, IGA and C-DLQI showed significant improvements in scores from those observed at baseline to the last treatment of dupilumab. Most reported adverse effects on dupilumab were conjunctivitis and infection site reactions. All studies reported that dupilumab was well-tolerated. Limitations: Limitations include the low number of studies available and observation periods of up to 16 weeks, which may be too short to evaluate the drug's effectiveness and occurrence of adverse effects. This also limits our knowledge on whether there are sustained benefits and/or diminished efficacy as well as long-term side effects. Conclusion: Thus far, the data demonstrates dupilumab to be safe and effective in the management of moderate-to-severe atopic dermatitis in children aged 6– 11 years. Future studies should evaluate long-term dupilumab use and sustained effects. Keywords: pediatric, pediatric dermatology, atopic dermatitis, dupilumab Atopic dermatitis (AD) is one of the most common inflammatory skin diseases affecting approximately 15–25% of children. 1 It is characterized by outbreaks of pruritic skin lesions and xerosis that classically manifest in early childhood. 2 Comorbid conditions including asthma, food allergies, eosinophilic esophagitis, sleep impairment, as well as mental health and behavioral problems that negatively impact the quality of life of both those affected and their families. 3 Food allergies and eosinophilic esophagitis are early components of atopic march, where such cutaneous manifestations may precede the onset of secondary pathologies and dermatologists represent the sentinels for the early identification of this group of patients with AD. 4 Significant medical, personal, societal, and financial burdens are also associated with AD. Estimated annual costs for families to care for a child with AD are comparable to those of a child with insulin-dependent diabetes and much higher than those of a child with asthma. 5 AD can be difficult to treat, however, there are a number of available treatment options that aim to reduce symptoms, prevent exacerbations, and minimize therapeutic risks. 1 Initial treatment for pediatric AD consists mostly of topical emollients and corticosteroids (TCs). 6 TCs are typically well-tolerated medications when used properly; however, TCs pose higher risks in the pediatric population given increased absorption due to a higher body surface area-to-weight ratio. 1,6 Alternative treatments include topical calcineurin inhibitors (TCIs), particularly for sensitive skin sites such as the face and skin folds. While TCIs have the advantage of not imposing risk for cutaneous atrophy, TCIs are not as effective as TCs and are more costly. 1 Although phototherapy is another treatment option available, it is not commonly used in pediatric populations as it requires biweekly visits to the doctor's office and not all healthcare facilities have access to the equipment. 1 Systemic corticosteroids and off-label drugs (cyclosporine, methotrexate, azathioprine) can also be used, but management with these is challenging. These medications require forewent lab morning, increase the risk of systemic adverse effects, and are not recommended for long-term use. 7,8 Emerging drug therapies for AD target its immune response elements. AD is characterized by an immune response that increases the expression of cytokines IL-4-, IL-13, and IL-5 secreted from Th2 helper T-cells. Dupilumab is a fully human monoclonal a -Abstract Truncated-

Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry

THE EFFECT OF DUPILUMAB ON LUNG FUNCTION BY ALLERGEN SENSITIZATION STATUS IN PEDIATRIC ASTHMA

Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: an Analysis of a Randomized, Double-Blind Phase III Study

Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma

Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry

Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population-based cohort study

Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis

The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: Results from a placebo-controlled, phase 3 study

509 - Dupilumab improves disease severity in children less than 12 years of age with moderate-severe AD: interim results from PEDISTAD real-world registry

Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma

The Application of Dupilumab to Pediatric Patients Aged 6–11yrs with Moderate-to-Severe Atopic Dermatitis Whose Disease is Not Adequately Controlled: The Clinical Data so Far

Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE Study

Real world outcomes of children treated with dupilumab for moderate-to severe atopic dermatitis: A single centre retrospective observational UK study

Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

Dupilumab Efficacy in Children With Type 2 Asthma Receiving High/Medium-Dose ICS (VOYAGE)

Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study

Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study

Effect of dupilumab on small airway dysfunction in real-life severe asthma: Japanese multi-center prospective cohort

Severe pediatric asthma therapy: Dupilumab

Higher prevalence of dupilumab-induced ocular surface disease in Atopic Dermatitis compared to Asthma patients: a real life, observational study.

Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: A population-based cohort study